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Abstract
The high mortality rate of lung cancer patients is mainly due to the late stage at which lung cancer is diagnosed. For
effective cancer prevention programs and early diagnosis, better blood-based markers are needed. Hence, blood-based
microarray profiling of microRNA (miR) expression was performed in preoperative serum of 21 non-small cell lung cancer
(NSCLC) patients and 11 healthy individuals by microfluid biochips containing 1158 different miRs. Two out of the 30 most
dysregulated miRs were further validated in serum of 97 NSCLC patients, 20 patients with benign lung diseases and 30
healthy individuals by TaqMan MicroRNA Assays. Microarray profiling showed that miR-361-3p and miR-625* were
significantly down-regulated in serum of lung cancer patients. Their further evaluation by quantitative RT-PCR showed that
the levels of miR-361-3p and miR-625* were lower in NSCLC than in benign disease (p=0.0001) and healthy individuals
(p=0.0001, p=0.0005, respectively). Moreover, the levels of miR-625* were significantly lower in patients with large cell
lung cancer (LCLC, p=0.014) and smoking patients (p=0.030) than in patients with adenocarcinoma and non-smoking
patients, respectively. A rise in the levels of both miRs was observed in the postoperative samples compared with the
preoperative levels (p=0.0001). Functional analyses showed that Smad2 and TGFß1 are not dysregulated by miR-361-3p
and miR-625* in the lung cell line A549, respectively. Our present pilot study suggests that miR-361-3p and miR-625* might
have a protective influence on the development of NSCLC, and the quantitative assessment of these miRs in blood serum
might have diagnostic potential to detect NSCLC, in particular in smokers.
Citation: Roth C, Stu ¨ckrath I, Pantel K, Izbicki JR, Tachezy M, et al. (2012) Low Levels of Cell-Free Circulating miR-361-3p and miR-625* as Blood-Based Markers for
Discriminating Malignant from Benign Lung Tumors. PLoS ONE 7(6): e38248. doi:10.1371/journal.pone.0038248
Editor: Kin Mang Lau, The Chinese University of Hong Kong, Hong Kong
Received January 24, 2012; Accepted May 2, 2012; Published June 4, 2012
Copyright:  2012 Roth et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by the Erich und Gertrud Roggenbuck-Stiftung, Hamburg. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hschwarz@uke.uni-hamburg.de
Introduction
Worldwide, lung cancer is the leading cause of cancer-related
death. The carcinoma develops in four major histological types
comprising squamous cell lung cancer (SQCLC), adenocarcinoma
(ADC) and large cell lung cancer (LCLC) of non-small cell lung
cancer (NSCLC), and small cell lung cancer (SCLC) [1]. In the
majority of cases the patients develop NSCLC which is associated
with an overall 5-year survival of only 15% and a high rate of
tumor recurrence [2]. Lung cancer may be caused by exposures to
etiologic agents, such as asbestos and cigarette smoke, and by
advanced age [3]. Regrettably, not all patients with lung cancer
have an operable tumor. The current therapeutic strategies for
lung cancer include combinations of cytotoxic chemotherapy and
targeted biological therapies, such as bevacizumab and erlotinib
[4]. However, adjuvant chemotherapy only results in a modest
extension of survival and is significantly toxic for the patients.
Furthermore, many patients are not sensitive to treatment due to
the resistance of cancer cells. Although tomography-based
population screenings for identifying high-risk individuals are
carried out, additionally minimally invasive biomarkers allowing
repeated blood withdrawals are urgently needed to detect lung
cancer early and personalize care of the patients [5].
Since microRNAs (miRs) are known to be detectable as stable
molecules in blood of cancer patients [6], they have potential to
become new blood-based biomarkers for lung cancer. MiRs are
small regulatory, non-coding RNA molecules of approximately 22
nucleotides. They negatively regulate their target mRNA, e.g. the
transcripts of tumor suppressor genes, by binding sequence-
specifically to complementary sites within the 39 untranslated
regions (UTRs) of mRNAs and inhibit their translation into
polypeptides or degrade their target mRNAs [7]. In addition to
their role in the repression of translation in proliferating cells, they
also mediate activation of translation in G1/G0 arrest of the cell
cycle [8]. This regulation occurs on at least two levels. MiRs seem
to be involved in the regulation of different cellular processes, e.g.
apoptosis, hematopoietic cell differentiation, metabolism, neural
development and metastasis [9,10,11]. Since half of human miRs
are located in fragile chromosomal regions, which can exhibit
amplifications, deletions or translocations, their expression is
frequently dysregulated during tumor development [12]. Their
expression may be either down- or upregulated in cancer cells as
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sive or oncogenic functions. Specific miRs play critical roles in
regulating tumorigenicity. Some miRs may be potential prognostic
biomarkers, such as miR-92a-2* in SCLC or miR-155, miR-130a,
let-7f and miR-30e-3p in NSCLC, whereas other miRs, such as
miR-31, are therapeutic or chemopreventive targets in lung cancer
[13]. To improve diagnosis and classification as well as to provide
clinical prognostic information in lung cancer, determination of
the miR signature in the blood serum of lung cancer patients
might be a useful minimally invasive approach.
In the current study we investigated which ones of over
thousand known miRs play a role as diagnostic marker in lung
cancer, performing a blood-based microarray profiling of miR
expression. We further validated two out of the 30 most
dysregulated miRs in serum of NSCLC patients in comparison
to patients with benign lung disease and healthy individuals by
quantitative real-time PCR.
Materials and Methods
Ethics Statement
From each participant who was involved in the present study
and provided blood samples, written informed consent has been
obtained. The use of medical records and blood was approved by
the ethics committee of the Medical Board Hamburg (Ethikkom-
mission der Hamburger A ¨rztekammer, Ko ¨rperschaft des o ¨ffentli-
chen Rechts, Hamburg, chief executive officer Dr. rer. nat. S.
Schrum).
Patient design and healthy controls
During July 1993 to January 2011, blood serum samples were
taken from 118 NSCLC patients before surgery. Due to the
limited availability of serum volumes, serum samples from 21
NSCLC patients were used for microRNA profiling, whereas
serum samples from 97 NSCLC patients were used for the further
validation by quantitative real-time PCR. In 20 cases of these 97
NSCLC patients serial samples were collected approximately two
weeks after surgery and before chemotherapy. Serum samples of
20 patients with benign lung disease (9 with benign round foci, 9
with chronic obstructive pulmonary disease, 1 with chronic
inflammatory pneumonitis and 1 with pulmonary hypertension)
were collected between March 2004 and April 2011 as control
cohort. Additionally, 30 healthy controls with no history of cancer
and in good health based on self-report were recruited. Table 1
summarizes the parameters of the validation cohorts (97 NSCLC
patients, 20 patients with benign lung disease, 30 healthy
individuals) those serum samples were analyzed by quantitative
real-time PCR. The established risk factors were (e.g. type of
carcinoma or smoking behavior) were not available for some
patients resulting in divergent numbers of patients in the
subgroups listed in table 1.
MicroRNA profiling
MicroRNA profiling was performed with serum samples
derived from 21 NSCLC patients and 11 healthy individuals.
Total RNA was isolated from 1 ml blood serum of 21 NSCLC
patients and 11 healthy individuals by Trizol LS Reagent
(Karlsruhe, Germany, Invitrogen) according to the manufacturer’s
protocol. Blood-based microarray profiling was performed on
microfluid biochips (Febit Biomed GmbH, Heidelberg, Germany)
containing 1158 miRs as published in the current Sanger miRBase
release (version 15.0 April 2010 for homo sapiens). For hybrid-
isation of the miRs the Microfluid Primer Extension Assay was
used. Specific elongation of bound miRs was carried out by adding
Klenow fragment of DNA polymerase I into the channels of
microfluid biochips.
Reference miR
As there is no consensus concerning the normalization of
circulating miRs, we evaluated two references (RNU6B and miR-
1233) for our miR analyses. MiR-1233 was chosen, because this
miR showed the smallest variation between NSCLC patients and
healthy individuals as measured by the blood-based microarray.
Additionally, RNU6B was chosen, because this miR was
recommended by the manufacturer (Applied Biosystems, Darm-
stadt, Germany). As observed by Huang et al. for colorectal cancer
[14], we also measured variable values of RNU6B in our blood
serum samples. Therefore, miR-1233 was used for normalization
of our miR analyses. We calculated mean values of 12.07
(SD=2.10), 12.96 (SD=1.68) and 12.73 (SD=2.90) for miR-
1233 in serum of NSCLC patients, healthy controls and patients
with benign lung disease, respectively.
Quantitative real-time PCR
For isolation of total RNA from 400 ml human blood serum of
97 NSCLC patients, 20 patients with benign lung disease and 30
healthy individuals the mirVana PARIS kit (Ambion, Darmstadt,
Germany) was used. Reverse transcription was performed by the
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosys-
tems). RNA extraction and cDNA conversion are described
elsewhere [15]. The cDNA of all microRNAs was first pre-
amplified in 7.5 ml Taq PCR Mastermix and 0.75 ml TaqMan
MicroRNA Assay mix using the Taq PCR Mastermix Kit
(Qiagen, Hilden, Germany). The PCR was run on a MJ Research
PTC-200 Peltier Thermal Cycler (Global Medical Instrumenta-
tion): 1 cycle at 95uC for 5 min, 15 cycles at 95uC for 20 s, 60uC
for 20 s and 72uC for 20 s, and a terminal cycle at 72uC for 5 min.
For quantitative real-time PCR, the miR-specific TaqMan
MicroRNA Assays (Applied Biosystems) for miR-1233 (reference
miR), miR-361-3p and miR-625* were used. In a 10 ml-reaction,
3 ml preamplified cDNA were mixed with 5 ml TaqMan Universal
PCR Master Mix No AmpErase UNG and 0.5 ml miR-specific
TaqMan MicroRNA Assay Mix on a twin-tec real-time PCR plate
(Eppendorf, Hamburg, Germany). The quantitative real-time
PCR reaction was performed at 95uC for 10 min and for 40 cycles
at 95uC for 15 s and 60uC for 60 s on a Mastercycler Realplex
(Eppendorf).
The obtained data of the miR expression levels were calculated
and evaluated by the DCt method as follows: DCt=mean value Ct
(reference miR-1233) - mean value Ct (miR of interest). The
relative expression of miR of interest corresponded to the
2‘(DCt)*1000 value.
Cell culture and transient transfection of miR-361-3p and
miR-625*
The lung cancer cell line A549 was cultured in RPMI medium
containing 10% FCS (PAA Laboratories, Co ¨lbe, Germany),
2 mMol L-glutamine (Invitrogen) and 200 U/ml penicillin/
streptomycin under standard conditions (37uC, 10% CO2).
To analyze whether miR-361-3p and miR-625* have an
influence on the expression of Smad2 or the transforming growth
factor beta 1 (TGFb1), 3*105 of lung cancer cells were seeded in 6-
well plates (NUNC, Roskilde, Denmark) and transfected with the
double-stranded miScript miRNA Mimics hsa-miR-361-3p and
hsa-miR-625* at final concentrations of 20 mM (Qiagen) and/or
with the single-stranded miScript Inhibitors hsa-miR-361-3p and
hsa-miR-625* at final concentrations of 200 mM (Qiagen) with
Serum miR-361-3p and miR-625
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Diagnostics, Mannheim, Germany). After incubation of 48 hours,
total RNA and protein were extracted using peqGOLD TriFast
(Peqlab, Erlangen, Germany) according to the manufacturer’s
instructions.
Quantitative real-time PCR and Western Blot of Smad2
and TGFb1
To determine the mRNA expression of Smad2 and TGFb1, a
total of 200 ng RNA from basal and transfected A549 cells was
reverse transcribed using the First strand cDNA synthesis kit
Table 1. Patients’ characteristics and correlation of serum RNA and relative levels of circulating miRs with clinical and
histopathological parameters of the validation cohort.
Parameters Patients (%) Total RNA (ng/ml) miR361-3p miR625*
NSCLC Patients Mean, Median (95% Confidence Interval)
Total 97
Age 65 years
(range 37–84 years)
#Type of carcinoma
ADC 39 (45.3)
a7.4, 6.1 (5.9–8.9) 9.6, 3.3 (0.3–18.8)
b1228.1, 806.6 (923.3–1532.9)
SQCLC 35 (40.7)
a7.4, 6.7 (6.0–8.7) 20.8, 4.5 (23.7–45.4)
b2535.6, 801.1 (2488.3–5559.6)
LCLC 12 (14.0)
a11.8, 8.6 (5.4–18.3) 6.2, 2.0 (21.8–14.2)
b1044.9, 322.5 (2370.1–2459.9)
Distant metastasis
£M0 52 (89.7) 7.5, 5.7 (6.1–8.9) 12.9, 2.0 (23.4–29.2) 1983.4, 661.3 (235.1–4002.0)
$M1 6 (10.3) 9.4, 7.4 (1.9–16.8) 15.7, 3.2 (212.6–44.1) 748.4, 435.2 (89.6–1407.2)
#Tumor stage
pT1-2 73 (76.8) 7.9, 6.7 (6.6–9.3) 6.3, 3.4 (3.9–8.6) 1112.3, 756.1 (827.9–1396.7)
pT3-4 22 (23.2) 7.8, 5.9 (5.7–9.8) 35.0, 3.2 (27.1–77.1) 3301.2, 648.4 (21620.0–8222.3)
#Lymph node metastasis
N0 47 (51.6) 7.9, 6.6 (6.2–9.6) 6.6, 2.7 (3.0–10.3) 1077.2, 582.4 (668.3–1486.1)
N1-3 44 (48.4) 8.1, 6.6 (6.4–9.7) 20.0, 4.0 (20.7–40.7) 2217.4, 756.1 (2169.6–4604.3)
#Grading
I-II 38 (42.7) 7.2, 5.7 (5.6–8.8) 16.4, 4.0 (25.9–38.7) 2521.4, 794.6 (2254.7–5297.6)
III-IV 51 (57.3) 8.0, 7.6 (6.9–9.2) 10.4, 2.7 (2.5–18.4) 1029.7, 653.7 (673.5–1386.0)
#Fumatorium
positive 28 (80) 9.7, 7.2 (6.6–12.9) 16.9, 1.6 (213.8–47.7)
e2320.0, 405.4 (21520.9–6160.8)
negative 7 (20) 4.9, 5.0 (2.6–7.3) 4.1, 3.4 (0.4–7.8)
e1525.1, 1604.0 (500.8–2549.4)
Patients with benign lung disease
Total 20
Age 65 years 7.4, 6.3 (5.3–9.4) 47.4, 19.6 (8.9–85.8) 4229.2, 3605.0 (2522.2–5936.2)
(range 37–84 years)
Diagnosis
benign round foci 9 (45) 6.6, 5.9 (3.8–9.4)
d90.2, 57.1 (3.6–184.0) 4842.6, 3415.8 (400.3–9284.9)
others 11 (55) 7.9, 6.5 (4.7–11.2)
d16.2, 14.2 (8.6–23.7) 3783.1, 3823.8 (2765.6–4800.6)
#Fumatorium
positive 11(55) 8.3, 6.1 (4.8–11.8) 35.5, 24.8 (10.9–60.2) 3094.7, 3226.6 (2082.7–4106.7)
negative 9 (45) 6.0, 6.3 (4.7–7.4) 56.8, 36.0 (29.6–143.2) 5515.3, 3784.2 (1921.7–9109.0)
Healthy individuals
Total 30
Age 40 years 2.9, 2.7 (2.4–3.4) 27.9, 17.1 (14.2–41.6) 1589.2, 1293.9 (1008.5–2169.9)
(range 21–66 years)
ap=0.048,
bp=0.014,
ep=0.030,
dp=0.031;
£M0, patients with localized NSCLC;
$M1, patients with metastatic NSCLC;
#M0 patients;
p values as determined by Mann Whitney-U test.
doi:10.1371/journal.pone.0038248.t001
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levels were subsequently quantified by real-time PCR using the
Maxima SYBR Green/ROX qPCR Master Mix (Fermentas) and
the following primers: TGFb1 forward: 59-
GGCCCTGCCCCTACATTT-39, and reverse: 59-
CCGGGTTATGCTGGTTGTACA -39, Smad2 forward: 59-
TACCGAAGGCAGACGGTAACAAGT-39, and reverse: 59-
GACATGCTTGAGCAACGCACTGAA-39, and GAPDH for-
ward: 59- CCCCACACACATGCACTTACC-39 and reverse: 59 -
CCTAGTCCCAGGGCTTTGATT- 39.
Protein levels of Smad2 and TGFb1 in basal and transfected
A549 cells were investigated by Western blot analysis. Thirty mgo f
cell lysates were electrophoretically separated and blotted onto a
PVDF membrane (Millipore, Billerica, USA) which was subse-
quently incubated with antibodies specific for Smad2 (1:1000, Cell
Signaling Technology, Boston MA, USA) and TGFb1 (1:1000)
overnight. The membrane was reprobed with the anti-Hsc70
antibody (Santa Cruz, Heidelberg, Germany) overnight which
served as loading control. Detection of the proteins was carried out
using peroxidase-conjugated secondary antibodies (Dako,
Glostrup, Denmark) and the chemiluminescence ECL detection
Kit (Amersham).
Statistical analysis
Based on bioinformatic analysis of microRNA profiling, the
most dysregulated 30 probes were detected by quotation of mean,
median, or variance, parametric t-test, non-parametric Wilcoxon-
Mann-Whitney test, empirical Bayes statistics and the area under
the receiver operator characteristics (ROC) curves. For signifi-
cance tests raw p-values were adjusted. To detect possible clusters,
hierarchical clustering was carried out.
Two out of the 30 most dysregulated miRs were further
validated using the SPSS software package, version 18.0 (SPSS
Inc. Chicago, IL). For non-parametric comparisons, univariate
analyses of the Mann Whitney-U test of two independent
variables, Wilcoxon signed rank test of two dependent variables
and bivariate analyses of the Spearman-Rho test were used.
Missing data were handled by pairwise deletion. Diagnostic power
of the single markers was analyzed by ROC curves. Areas under
the curves (AUC) were calculated. A p-value,0.05 was considered
as statistically significant. All p-values are two-sided.
Results
MiR profiling using a blood-based microarray
For blood-based miR profiling, microfluid biochips containing
1158 different miRs were used to quantify the expression of miRs
in serum of 21 NSCLC patients and 11 healthy individuals. To
detect differentially regulated miRs, the quotation of median,
paired Student’s t-test and limma test were assessed. Dysregulated
miRs were detected by the highest absolute value of logarithmized
fold changes in comparison of NSCLC patients to healthy
individuals. The estimated raw p-values were adjusted for multiple
testing, to control the false discovery rate. Table 2 shows 30 most
differentially expressed miRs with the adjusted p-values as
determined by t-test and limma test. In addition, the normalized
median values of healthy individuals and NSCLC patients are
listed, and the comparison of these values in both cohorts indicates
the down- or up-regulated miRs (Table 2). A similarity matrix was
generated containing all pairwise similarities of the serum samples
of NSCLC patients and healthy controls. To detect potential
clusters in rows (transcripts) and columns (samples) of the
normalized expression matrix, hierarchical clustering was carried
out. For this analysis 30 miRs with highest overall variability as
listed in Table 2 were used (Fig. 1A). In Fig. 1B, the volcano plot
shows the comparison of both cohorts (healthy individuals vs.
NSCLC patients) and 2 most significantly dysregulated miRs.
Based on these array data (Table 2, Fig. 1), we chose miR-361-3p
and miR-625*, which were significantly down-regulated in
NSCLC patients, for further validation studies.
Quantification of total RNA, miR-361-3p and miR-625* by
qRT-PCR
The concentrations of miR-361-3p and miR-625* were further
evaluated in blood serum of 97 NSCLC patients, 20 patients with
benign lung disease and 30 healthy individuals. The box plots in
Fig. 2 compare the relative levels of total RNA and miRs in
healthy individuals and patients with benign or malignant lung
disease. Patients with benign (p=0.0001) and malignant disease
(p=0.0001) displayed significant higher concentrations of total
RNA in their blood than healthy individuals (Fig. 2A). In contrast,
the levels of miR-361-3p was significantly decreased in NSCLC
patients in comparison to healthy individuals (p=0.0001) and
patients with benign lung disease (p=0.0001), whereas the levels
of this miR were similar in healthy individuals and patients with
benign lung disease (Fig. 2B). Surprisingly, the relative transcript
levels of miR-625* was significant higher in serum of patients with
benign lung disease than in healthy individuals (p=0.0001) and
NSCLC patients (p=0.0001) (Fig. 2C). However, the levels of this
miR were significantly lower in NSCLC than in benign disease
(p=0.0001) and healthy individuals (p=0.0005, Fig. 2C).
In order to determine the sensitivity and specificity of miR-361-
3p and miR-625* in distinguishing NSCLC patients from patients
with benign disease and healthy individuals, we performed ROC
analysis. The AUC values of miR-361-3p and miR-625* were
0.861 and 0.770, respectively, demonstrating the significant
difference of the transcript levels between NSCLC patients and
the two other cohorts (Fig. 2D). Thus, the yields of miR-361-3p
and miR-625* are cancer-specifically decreased in NSCLC
patients.
Albeit the cohort of 20 patients with benign lung disease was
small, we compared the serum concentrations of miR-361-3p and
miR-625* in patients with pulmonary round foci (n=9) with those
in patients with other benign lung diseases (9 chronic obstructive
pulmonary disease, 1 chronic inflammatory pneumonitis, 1
pulmonary hypertension). The statistical evaluation of serum
concentrations of the miRs in this cohort showed that patients with
other benign lung diseases had significantly lower serum levels of
miR-361-3p (p=0.031) than patients with round foci (Table 2).
Pre- and postoperative serum levels of circulating RNA
and miRs in NSCLC patients
In 20 NSCLC patients additional serum samples were collected
approximately two weeks after surgery and before the start of any
chemotherapy. The high preoperative concentrations of circulat-
ing total RNA significantly decreased in postoperative serum
samples (p=0.036, Fig. 3A). In contrast, serum levels of miR-361-
3p (p=0.001, Fig. 3B) and miR-625* (p=0.0001, Fig. 3C)
significantly increased after surgery. The postoperative levels of
RNA and miRs displayed similar levels to those of healthy
individuals or patients with benign lung disease.
Decreased serum levels of miR-625* in patients with
LCLC and smoking patients
We performed statistical analyses of the preoperative concen-
trations of circulating total RNA, miR-361-3p and miR-625* with
the clinical and histopathological data of the 97 NSCLC patients,
Serum miR-361-3p and miR-625
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ADC, the smoker subgroup had different histological types of
ADC, SQCLC and LCLC.
Fig. 4A shows the prevalence of serum values of miR-625* in
NSCLC patients with the different histological types, as well as in
non-smoking and smoking NSCLC patients, whereas Fig. 4B only
shows this prevalence in smoking NSCLC patients. As depicted in
Fig. 4A, LCLC patients (p=0.014) and smoking patients
(p=0.030) had significantly lower serum levels of miR-625* than
ADC patients and non-smoking patients, respectively. Within the
group of smoking patients, the LCLC patients had lower serum
values of miR-625* (p=0.001) compared to ADC patients
(Fig. 4B). In the cohort of the patients with benign lung tumors
the smoking patients also had lower levels of miR-625* than the
non-smoking patients, but this difference was not significant
(p=0.080). However, when we merged both cohorts of NSCLC
patients and patients with benign lung disease, we detected more
significantly lower serum levels of miR-625* in smoking patients
(p=0.002) than non-smoking patients (Fig. 4C). Regrettably, the
smoking behavior of healthy individuals was unknown to consider
the relationship of the levels of miR-625* with the smoker status of
healthy individuals.
Since there were only two cases with asbestos exposure in our
patient cohort, we could not examine whether the decrease in
miR-625* expression was associated with this carcinogen. Apart
from these associations, no further significant correlation between
clinical parameters and the serum values of miRs were detected.
MiR-361-3p and miR-625* do not affect the protein
expression of SMAD2 and TGF-ß1 in A549 cells
The cancer-specific decrease in transcript levels of miR-361-3p
and miR-625* in NSCLC patients provoked us to search for
potential targets of miR-361-3p and miR-625* in the miRbase
database [16]. The screening revealed potential binding affinities
of miR-361-3p to Smad2 and of miR-625* to TGFß1. To examine
whether expressions of Smad2 was regulated by miR-361-3p and
those of TGFß1 by miR-625*, we performed transfections of the
cell line A549 using mimics and inhibitors of miR-361-3p and
Table 2. Differentially regulated microRNAs in healthy individuals versus patients with NSCLC.
microRNA normalized median values
t-test adjusted
p-value
limma test adjusted
p-value
healthy NSCLC
miR-1228 7.73 8.71 0.22 0.12
miR-466 8.25 9.25 0.20 0.12
miR-1229 7.55 8.32 0.19 0.21
miR-4271 8.45 7.00 0.28 0.12
miR-1915 8.98 8.02 0.31 0.25
miR-582-5p 6.30 6.92 0.15 0.12
miR-190 6.37 6.95 0.14 0.12
miR-766 7.66 8.55 0.30 0.14
miR-4313 8.07 7.49 0.62 0.97
miR-1470 8.57 7.58 0.36 0.44
miR-718 7.96 6.83 0.22 0.02
miR-296-5p 8.09 7.28 0.54 0.44
miR-4298 7.89 8.65 0.28 0.34
miR-382 6.66 7.29 0.53 0.23
miR-1234 9.01 9.92 0.56 0.42
miR-19b 8.19 7.62 0.31 0.42
miR-302b 6.61 7.24 0.48 0.37
miR-361-3p 7.65 7.09 0.06 0.01
miR520-3p 6.71 7.64 0.19 0.06
miR-379 6.88 7.44 0.31 0.52
miR-1913 8.82 7.54 0.23 0.12
miR-449b* 7.11 7.72 0.06 0.14
miR-625* 8.33 7.00 0.16 0.01
let-7a 6.40 7.02 0.42 0.14
miR-574-5p 9.65 10.40 0.91 0.76
miR-185* 6.56 7.27 0.30 0.18
miR-4258 8.46 7.77 0.56 0.55
miR-324-5p 8.02 7.46 0.15 0.09
miR-4279 6.89 7.46 0.06 0.12
miR-197 6.82 7.45 0.19 0.25
doi:10.1371/journal.pone.0038248.t002
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which mimics the mature of endogenous miR-361-3p and miR-
625*, whereas the inhibitors are single-stranded, modified RNA
molecules which after transfection, specifically binds to mimics and
endogenous miR-361-3p and miR-625*, and inhibits their
function. The data of the quantitative real-time PCR using
gene-specific primers and Western blotting using antibodies
specific for SMAD2 and TGF-ß1 showed no effect of the mimics
and inhibitors on the RNA and protein levels of SMAD2 and
TGF-ß1. These findings indicate that miR-361-3p and miR-625*
do not target SMAD2 and TGF-ß1 (data not shown).
Discussion
In the present study we performed microarray profiling of 1158
different miRs in serum of 21 NSCLC patients and 11 healthy
individuals. Out of the 30 most dysregulated miRs of the array, we
selected the two most significantly down-regulated miRs (miR-
361-3p and miR-625*), which we validated further in serum of 97
NSCLC patients, 20 patients with benign lung disease and 30
healthy individuals by quantitative real-time PCR. Our data show
that in contrast to the elevated serum levels of total RNA in
NSCLC patients, the serum levels of both miRs decreased in
NSCLC patients compared with the levels in patients with benign
disease and healthy controls. Since these serum miR measure-
ments could discriminate NSCLC patients from benign lung
disease and healthy controls, their low serum levels may represent
a cancer-specific dysregulation with potential functional conse-
quences. This assumption is further supported by the observation
that the low transcript levels increased back to the normal levels in
NSCLC patients after surgical removal of their primary tumor.
Furthermore, the decreased serum levels of miR-625* correlated
with the LCLC subtype and the smoking behavior of NSCLC
patients.
To date, no study has quantified the transcript levels of miR-
361-3p and miR-625* in tumor tissue or blood. In our present
study, these both miRs could differentiate NSCLC from benign
lesions and healthy controls. Screening for their putative target
mRNA molecules in the miR database (miRBase) showed that
miR-361-3p may down-regulate the gene expression of paired-box
(PAX) [17] and ras-related rap2 protein RAP2B which belongs to
Ras superfamily of GTPases [18] by targeting the 39-UTR of the
corresponding mRNA molecules. As a result the down-regulation
of miR-361-3p might lead to higher protein levels of PAX and
RAP2B in NSCLC patients. PAX genes encode a family of paired-
box transcription factors which are required for the growth and
survival of cancer cells. Frequent PAX gene expression has been
identified in several tumor cell lines and primary tumor tissues,
amongst others lung cancer [17]. The preferred target mRNA
molecules of miR-625* seem to be growth factor pleiotrophin
(PTN) [19] and metalloproteinase with thrombospondin motifs-1
(ADAMTS-1) [20]. PTN is highly expressed in certain solid
cancers and activates its cell surface receptors, regulating multiple
functions including cell adhesion, cell migration, cell proliferation
and cytoskeletal stability [19]. Overexpression of ADAMTS-1
promotes pulmonary metastasis of Lewis lung carcinoma cells and
a proteinase-inactivated mutant of ADAMTS-1 inhibited their
metastasis, indicating that the prometastatic activity of ADAMTS-
1 requires its metalloproteinase activity [20]. These examples of
the miR database might allude to the significant down-regulation
of miR-361-3p and miR-625* and their role in NSCLC.
Due to the high proliferation and turnover rate of tumor cells in
the primary tumor, it was surprising to detect reduced concentra-
tions of circulating miR-361-3p and miR-625* in serum of our
NSCLC patient cohort. Alike the elevated serum levels of total
RNA induced by necrosis or apoptosis, one might expect that the
increased cell death also results in increased release of miRs in
these patients. We cannot explain this phenomenon and speculate
Figure 1. MiR profiling by a blood-based microarray. Hierarchical cluster heat map of miR microarray was performed using microfluid biochips
containing 1158 different miRs with serum of 21 NSCLC patients and 11 healthy individuals. The colored representation of samples and probes is
ordered by their similarity with a dendogram on top (clustering of samples) and on the right side (clustering of probes) (A). Volcano plot was drawn
for comparison of miRs between NSCLC patients and healthy individuals. The two most dysregulated miRs are highlighted in blue on top right (B).
doi:10.1371/journal.pone.0038248.g001
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Moreover, the low levels could also be caused by an altered
enzymatic activity in blood or a modulated expression of the
enzyme Dicer that is essential for the biogenesis of mature miRs
[21,22]. However, these effects might also influence the transcript
level of other miRs. A further explanation could be that the
primary tumor affects lymphocytes in a paracrine manner
resulting in the reduced expression of miR-361-3p and miR-
625*. Since no lymphocytes were available from our present
patient cohort, we intend to investigate this hypothesis in the
future using another NSCLC patient cohort with matched serum
and lymphocyte samples.
Increased frequency of cigarette smoking is associated with lung
cancer risk. Therefore, we also investigated the molecular
relationship of cigarette smoking of lung cancer patients with the
miR concentrations. Whereas all non-smoking patients had an
ADC, the smoking patient subgroup had different histological
types of ADC, SQCLC and LCLC. Statistical analysis showed that
NSCLC patients with a LCLC and smoking patients had
significantly lower serum levels of miR-625* than ADC and
non-smoking patients, respectively. Within the subgroup of
smoking patients, LCLC patients had the lowest miR-625* levels.
No significant decrease was observed in non-smoking, ADC and
SQCLC patients. Thus, our findings may support the notion that
the dysregulation of serum miR-625* in smoking patients may be
related to LCLC. In the cohort of the patients with benign lung
tumors the smoking patients also had lower levels of miR-625*
than the non-smoking patients, but this difference was not
significant. However, when we merged both cohorts of patients
with malignant and benign lung tumors, we detected more
significantly lower serum levels of miR-625* in smoking patients
than non-smoking patients. Although we do not know the smoking
status of healthy individuals, these findings could allude to the
tumor-specific (but not the cancer-specific) decrease in the serum
levels of miR-625* in smoking patients. However, in our study the
smoking status was only known of few patients. Therefore, further
investigation is required using larger patient cohorts, and
functional validation of miR-625* is planned to explore a causative
relationship. In lung cancer tissues, the relationship with smoking
status has also been described for other miRs [23,24,25]. Among
NSCLC patients, low expression levels of miR-143 were
significantly correlated with smoking behavior [24]. In individuals
with a history of cigarette smoking, miR-218 expression was
significantly reduced [23]. A link between miR-218 down-
regulation and cigarette smoking was demonstrated by exposing
human bronchial epithelial cells to cigarette smoke extract which
decreased miR-218 expression levels [25].
As miRs are subject to complex regulatory mechanisms and
bind to several different target mRNA molecules, we examined
whether KRAS is a target of miR-625*. KRAS mutations were
reported to be almost entirely limited to lung cancers in smokers
[26]. However, screening of miR-625* in the miRbase database
[16] revealed no binding, but binding affinity to TGFß1. As a
multifunctional regulatory protein, TGFß1 controls many cellular
functions, such as cellular proliferation, differentiation, migration,
apoptosis, adhesion, angiogenesis, immune surveillance and
survival. In carcinogenesis, TGFß1 has been suggested to play a
dual role, acting as a tumor suppressor in early stages and a tumor
promoter in later stages, by enhancing tumor cell motility,
immunosuppression and invasiveness. Increased circulating levels
Figure 2. Evaluation of the diagnostic relevance of levels of total RNA and miRs in serum of healthy individuals, patients with
benign lung disease and NSCLC patients. The box plots show the different, relative amounts of total RNA (A), miR-361-3p (B) and miR-625* (C)
which circulate in blood of healthy individuals (n=30), patients with benign lung disease (n=20) and NSCLC patients (n=97). The relative transcript
levels of miRs were determined by the low cycle threshold (Ct) values. As determined by Mann and Whitney-U test, the significant p values of the
statistical evaluations of serum RNA and miR levels are indicated. The ROC analysis shows the profile of sensitivity and specificity of miR-361-3p and
miR-625* concentrations to discriminate NSCLC patients from patients with benign disease and healthy individuals (D). The AUC values and
confidence intervals are indicated.
doi:10.1371/journal.pone.0038248.g002
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consequently lung cancer development and prognosis [27]. The
intracellular signalling of TGFß1 is mediated by Smads. In the
epithelial-mesenchymal transition (EMT) the increased transcrip-
tional activity of phosphorylated Smad2 and 3 activates the
expression of target genes, such as TGF-b1, MMP-2, MMP-9,
plasminogen activator inhibitor type-1, vascular endothelial
growth factor, Snail and Slug, thus promoting cancer cell mobility
and invasion [28]. Of the numerous potential targets of miR-361-
3p and miR-625*, we chose Smad2 and TGFß1 for our analyses.
To examine whether Smad2 is regulated by miR-361-3p, and
TGFß1 by miR-625*, we performed functional analyses. Howev-
er, Western blot analyses showed no effect of 361-3p and miR-
625* on Smad2 and TGFß1 protein expression in the lung cell line
A549, respectively.
Interestingly, the differentially expressed miRs detected in our
blood-based microarray profiling are different to those listed in
previously published profiling studies [24,29]. As far as we know,
miR expression profiling in serum of lung cancer patients have
only been carried out in three studies [30,31,32]. Foss et al. used a
miR expression system containing 880 mature miRs and showed
the utility of miR-1254 and miR-574-5p as serum-based
biomarkers for minimally invasive screening [31]. One of the
two other studies which applied Solexa sequencing showed that
the signature of miR-486, miR-30d, miR-1 and miR-499 was an
independent predictor of overall survival [32]. The other study
showed that the elevated transcript levels of miR-25 and miR-223
in serum were blood-based biomarkers of NSCLC patients [30].
The detection of divergent miR signatures in microarray assays
could mainly be due to the use of serum and the investigation of
circulating miRs, but also to the different composition of the
patient cohorts and the methodological differences used in the
profiling studies. For example, microarrays can include precursor
or mature miRs, while we used mature miRs for probe
hybridization. Moreover, the number of miRs in our microfluid
biochips was upgraded and contained 1158 different miRs, and
therefore, more miRs than in arrays used in previous studies.
In our study we additionally quantified the miR levels in the
serum of patients with benign lung disease, because on suspicion of
a tumor it is important to distinguish between malignant and
benign lesions. The comparison allows ascertaining that the
dysregulation of serum miRs is cancer-specific and not only tumor-
specific or the consequence of inflammation. Therefore, to
accurately examine the pathology of a tumor in clinical practice,
it is of high interest to establish minimal-invasive biomarkers able
to discriminate a malignant from a benign tumor. To our
knowledge, there are five publications dealing with circulating
miRs in blood of NSCLC patients [30,31,32,33,34], and only one
recent study compared the concentrations of serum miRs in lung
cancer patients with those in patients with benign disease. The
authors of that study developed a test, based on the detection of 34
serum miRs that could identify patients with early stage NSCLC in
Figure 3. Comparison of total RNA and miR levels in pre- and postoperative serum samples of NSCLC patients. The box plots show the
different, relative amounts of total RNA (A), miR-361-3p (B) and miR-625* (C) which circulate in blood of healthy individuals (n=30), patients with
benign lung disease (n=20) and NSCLC patients (n=20) collected before and after surgery. As determined by Wilcoxon test, the significant p values
of the statistical evaluations of serum RNA and miR levels are indicated above the blots.
doi:10.1371/journal.pone.0038248.g003
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accuracy. The miR signature was able to distinguish between
benign and malignant lesions, and to capture the onset of the
malignant disease in individual patients over time [34].
In conclusion, we identified lung cancer-associated miRs by
microarray profiling on microfluid biochips and quantitative real
time PCR. Our results suggest a potential diagnostic relevance of
miR-361-3p and miR-625* as blood-based markers. To further
validate the clinical utility of these circulating miRs, a prospective
large-scale study is planned. In addition, further functional
analyses are intended, to characterize their cancer-specific role.
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